These results indicate that, in NSCLC, troglitazone enhances VEGF-A mRNA expression by increasing HIF-1α expression, and that the VEGF-A receptor is mainly NRP-1. The gene discussed is HIF1A; the disease is non-small cell lung carcinoma.